NASDAQ:PTIProteostasis Therapeutics Stock Price, Forecast & News

Proteostasis Therapeutics' stock was trading at $1.16 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PTI stock has increased by 19.0% and is now trading at $1.38. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Proteostasis Therapeutics.

Proteostasis Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Proteostasis Therapeutics.

Proteostasis Therapeutics Inc (NASDAQ:PTI) announced its quarterly earnings data on Friday, May, 15th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.07. View Proteostasis Therapeutics' earnings history.

5 brokers have issued twelve-month target prices for Proteostasis Therapeutics' shares. Their forecasts range from $3.00 to $8.00. On average, they anticipate Proteostasis Therapeutics' share price to reach $5.20 in the next year. This suggests a possible upside of 276.8% from the stock's current price. View analysts' price targets for Proteostasis Therapeutics.

News headlines about PTI stock have trended very negative on Thursday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Proteostasis Therapeutics earned a daily sentiment score of -3.3 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about Proteostasis Therapeutics.

Proteostasis Therapeutics saw a increase in short interest in June. As of June 15th, there was short interest totaling 3,080,000 shares, an increase of 10.0% from the May 31st total of 2,800,000 shares. Based on an average daily volume of 1,090,000 shares, the days-to-cover ratio is presently 2.8 days. Currently, 7.3% of the shares of the stock are sold short. View Proteostasis Therapeutics' Current Options Chain.

Some companies that are related to Proteostasis Therapeutics include Menlo Therapeutics (MNLO), Obseva (OBSV), Verrica Pharmaceuticals (VRCA), AMAG Pharmaceuticals (AMAG), OrganiGram (OGI), Spero Therapeutics (SPRO), Bicycle Therapeutics (BCYC), Concert Pharmaceuticals (CNCE), Verastem (VSTM), IDEAYA Biosciences (IDYA), IVERIC bio (ISEE), Hookipa Pharma (HOOK), Selecta Biosciences (SELB), Northwest Biotherapeutics (NWBO) and CymaBay Therapeutics (CBAY). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Amarin (AMRN), Micron Technology (MU), Rite Aid (RAD), Clearside Biomedical (CLSD), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Anavex Life Sciences (AVXL) and Syndax Pharmaceuticals (SNDX).

(PTI) raised $51 million in an initial public offering on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets served as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers.

Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI."

Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PTI stock can currently be purchased for approximately $1.38.

Proteostasis Therapeutics has a market capitalization of $71.97 million and generates $5 million in revenue each year. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Proteostasis Therapeutics employs 44 workers across the globe.

The official website for Proteostasis Therapeutics is www.proteostasis.com.

Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected]